Delving into the Latest Updates on Roche SpA with Synapse

Overview

Basic Info

Introduction

Roche SpA is a company that specializes in pharmaceutical services. Established in 1896 by Fritz Hoffmann-La Roche, the organization is based in Monza, Italy.

Tags

Otorhinolaryngologic Diseases

Nervous System Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

BRAF V600E	1

Author: Inzoli, Alessandro ; Battistini, Roberta ; Gaglione, Gianfranco ; Mannina, Donato ; Cardinale, Giovanni ; Santoro, Armando ; Murineddu, Marco ; Turrini, Mauro ; Fraticelli, Vincenzo ; Corradini, Paolo ; Cantore, Nicola ; Caparrotti, Giuseppe ; Barbiero, Valentina ; Santini, Simone ; Ladetto, Marco ; Mengarelli, Andrea ; Petrini, Mario ; La Nasa, Giorgio ; Martelli, Maurizio ; Gaidano, Gianluca ; Camera, Andrea ; Consoli, Ugo ; Ferreri, Andres J. M. ; Stelitano, Caterina ; Marino, Dario ; Musto, Pellegrino ; Arcaini, Luca ; Guarini, Attilio ; Liberati, Anna Maria ; Ronci, Benedetto ; Cerqueti, Manuela ; Massimi, Stefano ; Ferrando, Paola

Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included adult patients with CD20+ DLBCL or FL having received at least one full dose of IV RTX 375 mg/m2 during induction or maintenance. Patients on induction received ≥4 cycles of RTX SC 1400 mg plus standard chemotherapy and FL patients on maintenance received ≥6 cycles of RTX SC. Overall, 159 patients (73 DLBCL, 86 FL) were enrolled: 103 (54 DLBCL, 49 FL) completed induction and 42 patients with FL completed 12 maintenance cycles. ARRs were reported in 10 patients (6.3%), 3 (4.2%) with DLBCL and 7 (8.1%) with FL, all of mild severity, and resolved without dose delay/discontinuation. Treatment-emergent adverse events (TEAEs) and serious adverse events occurred in 41 (25.9%) and 14 patients (8.9%), respectively. Two patients with DLBCL had fatal events: Klebsiella infection (related to rituximab) and septic shock (related to chemotherapy). Neutropenia (14 patients, 8.9%) was the most common treatment-related TEAE. Two patients with DLBCL (2.8%) and 6 with FL (7.0%) discontinued rituximab due to TEAEs. 65.2% and 69.7% of patients with DLBCL and 67.9% and 73.6% of patients with FL had complete response (CR) and CR unconfirmed, respectively. The median time to events (EFS, PFS, and OS) was not estimable due to the low rate of events. At a median follow-up of 29.5 and 47.8 months in patients with DLBCL and FL, respectively, EFS, PFS, and OS were 70.8%, 70.8%, and 80.6% in patients with DLBCL and 77.9%, 77.9%, and 95.3% in patients with FL, respectively. The switch from IV to SC rituximab in patients with DLBCL and FL was associated with low risk of ARRs and satisfactory response in both groups. This trial was registered with NCT01987505.

01 Nov 2014·Value in HealthQ2 · MEDICINE

Organizational and Management Impact Analysis of Using the New Subcutaneous Formulation of Tocilizumab in Selected Italian Rheumatology Centers

Q2 · MEDICINE

Article

Author: Govoni, M ; Adami, S ; Ciancio, G ; Paolini, D ; Canciani, M ; Tomic, R ; Ravera, S ; Bianchino, L ; Viapiana, O ; Farina, M

Research & Reviews: Journal of Medical and Health Sciences

Nodolase: a review of efficacy

Author: Sarracino, Massimo

NODOLASE it's a new dietary supplement formulated with natural active and characterized by anti-inflammatory, anti-edema, analgesic and anti-oxidant effects.The aim of this review was to report the efficacy of NODOLASE in several patients.NODOLASE has been studied in patients with joint, tendons and muscle diseases, acute exacerbations of COPD and dental disease.In patients with wrist, ankle and knee sprain or with muscle strain as well as after plaster cast removal, NODOLASE resulted in a good efficacy in reducing pain and swelling.Furthermore, NODOLASE was able to significantly improve the joint function by a significant reduction of stiffness of at least 30% in all studies.In patients with mild to moderate acute exacerbations of COPD, NODOLASE has been added to the antibiotic therapy.However, compared to the broad-spectrum antibiotic therapy alone, the combination with NODOLASE has resulted in a faster improvement of cough and dyspnea.The results of this study showed that the antibiotic association with NODOLASE was able to improve better the respiratory function (FEV1) compared to antibiotic monotherapy.Also extremely important the addition of NODOLASE has determined a higher impact on the inflammatory pattern and in particular on IL-6, IL-8 and TNF-alpha in comparison to the antibiotic alone.NODOLASE in combination with analgesic in patients undergoing wisdom teeth has been investigated in a randomized study.In comparison with a traditional analgesic for 7 days the group treated with the combination NODOLASE + analgesic achieved better results in terms of efficacy with a lower incidence of pain local recurrence as well as a better recovery of the mandibular function.No adverse effects due to the administration of NODOLASE were reported.Treatment with NODOLASE was evaluated safe in all studies both by clinicians and patients.

100 Deals associated with Roche SpA

Login to view more data

100 Translational Medicine associated with Roche SpA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Other

Login to view more data